Key result
Prolonged dual antiplatelet therapy significantly increased the risk of composite bleeding events (OR 1.765) without significantly reducing major adverse cardiovascular and cerebrovascular events compared to standard 12-month therapy.
Why the study?
Whether prolonged DAPT in Chinese patients with ACS following emergency PCI with DES provides benefit or poses danger remained unclear.
Does prolonged DAPT (12-24 months) reduce MACCEs or increase bleeding compared to standard DAPT (12 months) in Chinese ACS patients undergoing emergency PCI with DES?
Cohort (n=2,249)
No
Does prolonged DAPT (12-24 months) reduce MACCEs or increase bleeding compared to standard DAPT (12 months) in Chinese ACS patients undergoing emergency PCI with DES?
In Chinese patients with ACS undergoing emergency PCI with DES, extending DAPT beyond 12 months significantly increases the risk of bleeding without providing a corresponding significant reduction in major adverse cardiovascular and cerebrovascular events.
Prolonged DAPT was associated with more bleeding without fewer MACCEs in Chinese ACS patients; leaves open optimal duration and warrants RCTs before practice change.
Background In patients with acute coronary syndrome (ACS), prolonged dual antiplatelet therapy (DAPT) may reduce ischemic events and increase the risks of bleeding events differently in different ethnic groups. However, whether prolonged DAPT in Chinese patients with ACS following emergency percutaneous coronary intervention (PCI) with drug-eluting stents (DES) will be beneficial or dangerous remains unclear. This study aimed to examine the potential benefits and risks of prolonged DAPT in Chinese patients with ACS who have undergone emergency PCI with DES. Methods This study included 2,249 patients with ACS who underwent emergency PCI. If DAPT was continued for 12 or 12–24 months, it was classified as the standard ( n = 1,011) or prolonged ( n = 1,238) DAPT group, respectively. The incidence of the following endpoint events was determined and compared between the two groups: composite bleeding event (BARC 1 or 2 types of bleeding and BARC 3 or 5 types of bleeding) and major adverse cardiovascular and cerebrovascular events (MACCEs) [ischemia-driven revascularization, non-fatal ischemia stroke, non-fatal myocardial infarction (MI), cardiac death, and all-cause death]. Results After a median period of 47 months of follow-up [47 (40, 54)], the rate of composite bleeding events was 13.2% ( n = 163) in the prolonged DAPT group and 7.9% ( n = 80) in the standard DAPT group [odds ratio (OR) 1.765, 95% confidence interval (CI) 1.332–2.338, p < 0.001]. The rate of MACCEs was 11.1% ( n = 138) in the prolonged DAPT group and 13.2% ( n = 133) in the standard DAPT group (OR 0.828, 95% CI 0.642–1.068, p = 0.146). The DAPT duration was further shown to be insignificantly correlated with MACCEs as per the multivariable Cox regression model (HR, 0.813; 95% CI, 0.638–1.036; p = 0.094). No statistically significant difference was observed between the two groups. However, the DAPT duration was a separate predictor of composite bleeding events according to the multivariable Cox regression model (HR 1.704, 95% CI 1.302–2.232, p < 0.001). Compared with the standard DAPT group, the prolonged DAPT group had substantially more BARC 3 or 5 types of bleeding events (3.0 vs. 0.9% in those with standard DAPT, OR 3.430, 95% CI 1.648–7.141, p < 0.001) and BARC 1 or 2 types of bleeding events (10.2 vs. 7.0% in those with standard DAPT, OR 1.500, 95% CI 1.107–2.032, p = 0.008). Conclusion The prolonged DAPT group had a considerably greater incidence of composite bleeding events than the standard DAPT group. No statistically significant difference was observed in the incidence of MACCEs between the two groups.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted a cohort in Acute coronary syndrome (n=2,249). Prolonged dual antiplatelet therapy vs. Standard dual antiplatelet therapy (12 months) was evaluated on Composite bleeding events (OR 1.765, 95% CI 1.332-2.338, p=<0.001). Prolonged dual antiplatelet therapy significantly increased the risk of composite bleeding events (OR 1.765) without significantly reducing major adverse cardiovascular and cerebrovascular events compared to standard 12-month therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: